Source:http://linkedlifedata.com/resource/pubmed/id/12916868
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2003-8-14
|
pubmed:abstractText |
The clinical features and outcome of 25 previously untreated aggressive non-Hodgidn's lymphoma (NHL) patients with hepatitis C virus (HCV) infection were evaluated retrospectively. The patients included 18 males and 7 females with a median age of 66 years. The median observation period for survivors was 32 months. Although there were no patients with hepatocellular carcinoma during the follow-up period, 7 patients had cirrhosis (LC) at the initiation of therapy for NHL. Seventeen patients (68%) had initial extranodal involvement including 2 cases with liver involvement. The 5-year overall survival (OS) rate in the whole group was 46%, and the 5-year relapse-free survival (RFS) rate of patients with complete response (CR) was 48%. Patients with non-cirrhosis (n = 18) showed better OS (P = 0.04) compared with patients with LC (n = 7) and 5-year OS rates were 55 and 21%, respectively. Fourteen patients died in the whole group; 4 of NHL and 2 of liver failure in the LC group and 8 of NHL in the non-cirrhotic group. Among the latter 8 patients, cumulative dose (CD) of doxorubicin (ADR) and cyclophosphamide (CPA) were significantly lower than those of survivors with non-cirrhosis. In conclusion, patients with HCV-positive aggressive NHL have a similar prognosis as HCV-negative aggressive NHL. In non-cirrhotic patients, attention should be paid to the CD of drugs required to cure the aggressive NHL.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1042-8194
|
pubmed:author |
pubmed-author:FujimakiKatsumichiK,
pubmed-author:FujisawaShinS,
pubmed-author:IshigatsuboYoshiakiY,
pubmed-author:KanamoriHeiwaH,
pubmed-author:KawanoTomokoT,
pubmed-author:KodamaFumioF,
pubmed-author:MotomuraShigekiS,
pubmed-author:TakabayashiMakiM,
pubmed-author:TomitaNaotoN,
pubmed-author:YamajiSatoshiS
|
pubmed:issnType |
Print
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1159-64
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12916868-Aged,
pubmed-meshheading:12916868-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12916868-Cyclophosphamide,
pubmed-meshheading:12916868-Doxorubicin,
pubmed-meshheading:12916868-Female,
pubmed-meshheading:12916868-Hepacivirus,
pubmed-meshheading:12916868-Hepatitis C,
pubmed-meshheading:12916868-Humans,
pubmed-meshheading:12916868-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12916868-Male,
pubmed-meshheading:12916868-Middle Aged,
pubmed-meshheading:12916868-Prognosis,
pubmed-meshheading:12916868-Retrospective Studies,
pubmed-meshheading:12916868-Survival Rate,
pubmed-meshheading:12916868-Treatment Outcome
|
pubmed:year |
2003
|
pubmed:articleTitle |
Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma.
|
pubmed:affiliation |
First Department of Internal Medicine, Yokohama City University School of Medicine, Japan. cavalier@ch-yamate.dlenet.com
|
pubmed:publicationType |
Journal Article,
Comparative Study
|